(Q51902631)

17 April 2018

title

Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. (English)

1 reference

17 April 2018

1 reference

Arif Khan

1

1 reference

17 April 2018

Anjana Bose

2

1 reference

17 April 2018

George S Alexopoulos

3

1 reference

17 April 2018

Carl Gommoll

4

1 reference

17 April 2018

Dayong Li

5

1 reference

17 April 2018

Chetan Gandhi

6

1 reference

17 April 2018

publication date

1 January 2007

1 reference

17 April 2018

Clinical Drug Investigation

published in

1 reference

17 April 2018

volume

27

1 reference

17 April 2018

issue

7

1 reference

17 April 2018

page(s)

481-492

1 reference

17 April 2018

The assessment of anxiety states by rating

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00044011-200727070-00005

Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

21 January 2018

1 reference

12 December 2020

Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports

1 reference

12 December 2020

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

12 December 2020

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

12 December 2020

A symptom questionnaire.

1 reference

12 December 2020

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

1 reference

12 December 2020

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

1 reference

12 December 2020

Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder

1 reference

12 December 2020

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

1 reference

12 December 2020

Which factors influence psychiatrists' selection of antidepressants?

1 reference

12 December 2020

The dual-action hypothesis: does pharmacology matter?

1 reference

12 December 2020

SSRI Antidepressant Medications: Adverse Effects and Tolerability

1 reference

12 December 2020

Continuity of antidepressant treatment for adults with depression in the United States.

1 reference

12 December 2020

Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses

1 reference

12 December 2020

Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range

1 reference

12 December 2020

Approaches to the enhancement of patient adherence to antidepressant medication treatment.

1 reference

12 December 2020

‘Real-life burden of depression’ surveys – GP and patient perspectives on treatment and management of recurrent depression

1 reference

12 December 2020

A New Depression Scale Designed to be Sensitive to Change

1 reference

12 December 2020

Use of effect size to determine optimal dose of duloxetine in major depressive disorder

1 reference

12 December 2020

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

12 December 2020

Pharmacotherapy to sustain the fully remitted state.

1 reference

12 December 2020

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

12 December 2020

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

1 reference

12 December 2020

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

12 December 2020

Tolerability and adherence issues in antidepressant therapy

1 reference

12 December 2020

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

12 December 2020

Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression

1 reference

12 December 2020

Residual symptoms in depression: can treatment be symptom-specific?

1 reference

12 December 2020

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

12 December 2020

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

1 reference

12 December 2020

Optimizing outcomes in depression: focus on antidepressant compliance

1 reference

12 December 2020

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

1 reference

12 December 2020

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

1 reference

12 December 2020

Discontinuing or switching selective serotonin-reuptake inhibitors

1 reference

12 December 2020

A comparison of factors used by physicians and patients in the selection of antidepressant agents

1 reference

12 December 2020

Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.

1 reference

12 December 2020

A rating scale for depression

1 reference

12 December 2020

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

12 December 2020

10.2165/00044011-200727070-00005

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018